alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Health and Human Services

###### National Institutes of Health

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:*                         National Institute of Nursing Research Special; Emphasis Panel Inflammatory Intervention.                    

*Date:*                         January 27, 2010.                    

*Time:*                         10 a.m. to 12 p.m.                    

*Agenda:*                         To review and evaluate contract proposals.                    

*Place:*                         National Institutes of Health, One Democracy Plaza, 6701 Democracy Boulevard, Bethesda, MD 20892 (Telephone Conference Call).                    

*Contact Person:*                         Tamizchelvi Thyagarajan, PhD, Scientific Review Officer, National Institute of Nursing Research, National Institutes of Health, 6701 Democracy Blvd., Bethesda, MD 20892, (301) 594-0343,                         *tamizchelvi.thyagarajan.nih.gov.*

Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

(Catalogue of Federal Domestic Assistance Program Nos. 93.361, Nursing Research, National Institutes of Health, HHS)

Dated: January 6, 2010.

Jennifer Spaeth,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 2010-413 Filed 1-12-10; 8:45 am]

BILLING CODE 4140-01-M
IN THE COURT OF APPEALS OF TENNESSEE

AT NASHVILLE

May 14, 2024

IN RE RAYDEN R. ET AL.

Appeal from the Juvenile Court for Williamson County

No. 39627 Sharon Guffee, Judge

___________________________________

No. M2024-00618-COA-R3-PT

___________________________________

A mother appeals the termination of her parental rights. Because the mother did not file 

her notice of appeal within thirty days after entry of the final judgment as required by 

Tennessee Rule of Appellate Procedure 4(a), we dismiss the appeal.

Tenn. R. App. P. 3 Appeal as of Right; Appeal Dismissed

ANDY D. BENNETT, W. NEAL MCBRAYER, and JEFFREY USMAN, JJ.

Gregory Wade Dawson, Nashville, Tennessee, for the appellant, Leila N. 

Katherine P. Adams, Nashville, Tennessee, for the appellee, Tennessee Department of 

Children’s Services.

Kevin D. Balkwill, Brentwood, Tennessee, Guardian ad Litem.

MEMORANDUM OPINION1

Leila N. (“Mother”) has filed a notice of appeal from a final judgment entered by 

the Juvenile Court for Williamson County on March 25, 2024, terminating her parental

rights. The guardian ad litem has moved to dismiss the appeal for failure to file a timely 

notice of appeal. Tennessee Rule of Appellate Procedure 4(a) requires that a notice of 

appeal be filed with the clerk of the appellate court within thirty days after entry of the 

judgment appealed. Mother did not file her notice of appeal until April 25, 2024, thirtyone days after entry of the judgment. Mother has not filed a response in opposition to the 

motion to dismiss. 

 

1 Under Tennessee Court of Appeals Rule 10, a case decided by memorandum opinion shall not be 

published and shall not be cited or relied on for any reason in any unrelated case.

05/23/2024
- 2 -

We are reluctant to dismiss an appeal involving the termination of parental rights 

based solely on counsel’s filing of the notice of appeal one day late. However, the time 

limit for filing a notice of appeal is mandatory and jurisdictional. Albert v. Frye, 145 

S.W.3d 526, 528 (Tenn. 2004); Binkley v. Medling, 117 S.W.3d 252, 255 (Tenn. 2003).

The failure to file a timely notice of appeal deprives this Court of jurisdiction to hear the 

matter. Flautt & Mann v. Council of City of Memphis, 285 S.W.3d 856, 869 (Tenn. Ct. 

App. 2008). While a trial court may, under unusual and compelling circumstances, grant 

an appellant relief from the failure to file a timely notice of appeal under Tennessee Rule 

of Civil Procedure 60, such relief must be sought in the trial court. Tenn. R. App. P. 4(a), 

Advisory Commission Comments; McCracken v. Brentwood United Methodist Church, 958

S.W.2d 792 (Tenn. Ct. App. 1997). This Court can neither waive nor extend the thirty-day 

time period.

The appeal is hereby dismissed for failure to file a timely notice of appeal. The case 

is remanded to the trial court for further proceedings consistent with this opinion. The costs 

are taxed to Leila N. for which execution may issue.

PER CURIAM
# C_2015398EN.01005301.xml

| 30.11.2015 | EN | Official Journal of the European Union | C 398/53 |
| --- | --- | --- | --- |

30.11.2015

EN

Official Journal of the European Union

C 398/53

---

Judgment of the General Court of 7 October 2015 — CBM v OHIM — Aeronautica Militare (TRECOLORE)

(Case T-365/14) (1)

1

((Community trade mark - Opposition proceedings - Application for Community figurative mark TRECOLORE - Earlier Community and national word and figurative marks FRECCE TRICOLORI - Relative ground for refusal - Likelihood of confusion - Article 8(1)(b) of Regulation (EC) No 207/2009))

(2015/C 398/67)

Language of the case: English

Parties

Parties

Applicant: CBM Creative Brands Marken GmbH (Zurich, Switzerland) (represented by: U. Lüken, M. Grundmann and N. Kerger, lawyers)

Applicant:

Defendant: Office for Harmonisation in the Internal Market (Trade Marks and Designs) (represented by: A. Folliard-Monguiral, acting as Agent)

Defendant:

Other party to the proceedings before the Board of Appeal of OHIM: Aeronautica Militare — Stato Maggiore (Rome, Italy)

Other party to the proceedings before the Board of Appeal of OHIM:

Re:

Re:

Action brought against the decision of the Fifth Board of Appeal of OHIM of 1 April 2014 (Case R 411/2013-5), relating to opposition proceedings between Aeronautica Militare — Stato Maggiore and CBM Creative Brands Marken GmbH.

Operative part of the judgment

Operative part of the judgment

The Court:

| 1. | Dismisses the action; |
| --- | --- |

1.

Dismisses the action;

| 2. | Orders CBM Creative Brands Marken GmbH to pay the costs. |
| --- | --- |

2.

Orders CBM Creative Brands Marken GmbH to pay the costs.

---

(1)  OJ C 253, 4.8.2014.

1

---
#### § 58.41 General.

Each testing facility shall be of suitable size and construction to facilitate the proper conduct of nonclinical laboratory studies. It shall be designed so that there is a degree of separation that will prevent any function or activity from having an adverse effect on the study.

[52 FR 33780, Sept. 4, 1987]
<PAGE>   1
                                                                   EXHIBIT 10.12

                     AMENDMENT NO. 2 TO LICENSING AGREEMENT


This Amendment No 2 to licensing Agreement (this "Amendment"), dated as of July
31, 1998 is entered into by and between the Dana-Farber Cancer Institute, Inc.,
a Massachusetts non-profit corporation ("DFCI"), and Corixa Corporation, a
Delaware corporation ("Corixa").


                                    RECITALS


A.    DFCI and Corixa are parties to that certain Licensing Agreement, dated as
      of January 1, 1995 (the "License Agreement"), as amended on September 15,
      1997, pursuant to which DFCI has granted to Corixa certain rights under
      the Patent Rights and Technical Information as defined therein.

B.    DFCI and Corixa desire to amend the License Agreement as set forth below.

NOW THEREFORE, the parties hereto agree to amend the License Agreement as
follows:


AMENDMENT

1.    DEFINITIONS

Except as otherwise defined herein, capitalized terms used in this Amendment
shall have the meanings designated in the License Agreement.

2.    DUE DILIGENCE

      The last line of Section 3.1 shall be deleted and replaced with the
      following:

      File IND                            By 12/98

3.    FULL FORCE AND EFFECT

Except as amended hereby, the License Agreement shall remain in full force and
effect in accordance with its terms.


IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be duly
executed as of the date first above written.

DANA-FARBER CANCER INSTITUTE, INC.     CORIXA CORPORATION

By: /s/ RUTH EMYANIZOFF, PH.D.         /s/ MARK MCDADE             
    --------------------------------   -------------------------------------
    Ruth Emyanizoff, Ph.D.             Mark McDade
    Director, Office of Technology     Chief Operating Officer
    Transfer


                                       1
[Federal Register Volume 75, Number 41 (Wednesday, March 3, 2010)]
[Notices]
[Page 9592]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-4356]


-----------------------------------------------------------------------

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Docket No. AC10-50-000; RM08-5-000]


National Grid USA; Notice of Filing

February 24, 2010.
    Take notice that on February 10, 2010, National Grid USA submitted 
a request for waiver of certain FERC Form No. 1 reporting requirements 
under Part 141 of regulations, 18 CFR 141, as established by the 
Federal Energy Regulatory Commission's Order No. 715.\1\
---------------------------------------------------------------------------

    \1\ Revisions to Forms, Statements and Reporting Requirements 
for Electric Utilities and Licensees, Order No. 715, 124 FERC ] 
61,273 (2008) (Order No. 715).
---------------------------------------------------------------------------

    Any person desiring to intervene or to protest this filing must 
file in accordance with Rules 211 and 214 of the Commission's Rules of 
Practice and Procedure (18 CFR 385.211 or 385.214). Protests will be 
considered by the Commission in determining the appropriate action to 
be taken, but will not serve to make protestants parties to the 
proceeding. Any person wishing to become a party must file a notice of 
intervention or motion to intervene, as appropriate. Such notices, 
motions, or protests must be filed on or before the comment date. On or 
before the comment date, it is not necessary to serve motions to 
intervene or protests on persons other than the Applicant.
    The Commission encourages electronic submission of protests and 
interventions in lieu of paper using the ``eFiling'' link at http://www.ferc.gov. Persons unable to file electronically should submit an 
original and 14 copies of the protest or intervention to the Federal 
Energy Regulatory Commission, 888 First Street, NE., Washington, DC 
20426.
    This filing is accessible on-line at http://www.ferc.gov, using the 
``eLibrary'' link and is available for review in the Commission's 
Public Reference Room in Washington, DC. There is an ``eSubscription'' 
link on the Web site that enables subscribers to receive e-mail 
notification when a document is added to a subscribed docket(s). For 
assistance with any FERC Online service, please e-mail 
<a href="/cdn-cgi/l/email-protection#d69093849599b8babfb8b385a3a6a6b9a4a296b0b3a4b5f8b1b9a0"><span class="__cf_email__" data-cfemail="591f1c0b1a16373530373c0a2c2929362b2d193f3c2b3a773e362f">[email protected]</span></a>, or call (866) 208-3676 (toll free). For 
TTY, call (202) 502-8659.
    Comment Date: March 10, 2010.

Kimberly Bose,
Secretary.
[FR Doc. 2010-4356 Filed 3-2-10; 8:45 am]
BILLING CODE 6717-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>
§ 74.1109 D&C Blue No. 9. ( a ) *Identity.* The color additive D&C Blue No. 9 is principally 7,16-dichloro-6,15 - dihydro - 5,9,14,18 - anthrazine-tetrone.
( b ) *Specifications.* D&C Blue No. 9 shall conform to the following specifications and shall be free from impurities other than those named to the extent that such impurities may be avoided by good manufacturing practice: Volatile matter (at 135 °C.), not more than 3 percent. Matter extractable by alcoholic HCl (0.1 ml of concentrated hydrochloric acid per 50 ml of 95 percent ethyl alcohol), not more than 1 percent. 2-Amino anthraquinone, not more than 0.2 percent. Organically combined chlorine in pure dye, 13.0-14.8 percent. Lead (as Pb), not more than 20 p/m. Arsenic (as As), not more than 3 p/m. Total color, not less than 97 percent.
( c ) *Uses and restrictions.* D&C Blue No. 9 may be safely used for coloring cotton and silk surgical sutures, including sutures for ophthalmic use, subject to the following restrictions: ( 1 ) The dyed suture shall conform in all respects to the requirements of the United States Pharmacopeia XX (1980).
( 2 ) The quantity of the color additive does not exceed 2.5 percent by weight of the suture.
( 3 ) When the sutures are used for the purposes specified in their labeling, the color additive does not migrate to the surrounding tissue.
( 4 ) If the suture is a new drug, a new-drug application approved pursuant to section 505 of the act is in effect for it.
( d ) *Labeling.* The label of the color additive shall conform to the requirements of § 70.25 of this chapter.
( e ) *Certification.* All batches of D&C Blue No. 9 shall be certified in accordance with regulations in part 80 of this chapter.
[42 FR 15654, Mar. 22, 1977, as amended at 49 FR 10090, Mar. 19, 1984; 58 FR 17098, Apr. 1, 1993]
Exhibit 32

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

Solely in connection with the filing of the Annual Report of Retractable Technologies, Inc. (the “Company”) on Form 10-K for the period ended December 31, 2010, as filed with the United States Securities and Exchange Commission on the date hereof (the “Report”), the undersigned Thomas J. Shaw, Chief Executive Officer, and Douglas W. Cowan, Chief Financial Officer, do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

 

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date:       March 31, 2011

 
|   | /S/   THOMAS J. SHAW                                                        |
|--------|-----------------------------------------------------------------------------|
|   | THOMAS   J. SHAW                                                            |
|   | PRESIDENT,   CHAIRMAN, AND                                                  |
|   | CHIEF   EXECUTIVE OFFICER                                                   |
|   |                                                                        |
|   | /S/   DOUGLAS W. COWAN                                                      |
|   | DOUGLAS   W. COWAN                                                          |
|   | VICE   PRESIDENT, CHIEF FINANCIAL OFFICER, AND PRINCIPAL ACCOUNTING OFFICER |

 

----
I 

118TH CONGRESS 

2D SESSION H. R. 7514 

To require the Secretary of Veterans Affairs to waive certain domestic content 

procurement preferences with respect to certain State home projects, 

and for other purposes. 

IN THE HOUSE OF REPRESENTATIVES 

MARCH 1, 2024 

Mr. FULCHER introduced the following bill; which was referred to the 

Committee on Veterans’ Affairs 

A BILL 

To require the Secretary of Veterans Affairs to waive certain 

domestic content procurement preferences with respect 

to certain State home projects, and for other purposes. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Waiving Arbitrary and 

5 Inconsistent Veteran home Requirements Act’’ or the 

6 ‘‘WAIVER Act’’. 


ssavage on LAPJG3WLY3PROD with BILLS
2 

•HR 7514 IH

1 SEC. 2. WAIVER OF DOMESTIC PROCUREMENT PREF2 ERENCE WITH RESPECT TO CERTAIN STATE 

3 VETERANS HOME PROJECTS. 

4 (a) IN GENERAL.—The Secretary of Veterans Affairs 

5 shall waive under subsection (b) of section 70914 of the 

6 Build America, Buy America Act (subtitle A of title IX 

7 of division G of Public Law 117–58) the domestic content 

8 procurement preference under such section with respect 

9 to a project for the construction of State home facilities 

10 with respect to which the application under section 8135 

11 of title 38, United States Code, for such project was sub12 mitted on or before April 15, 2022, and included in the 

13 ‘‘VA State Home Construction Grants Priority List FY 

14 2023’’, dated June 1, 2023. 

15 (b) STATE HOME DEFINED.—In this section, the 

16 term ‘‘State home’’ has the meaning given that term in 

17 section 101(19) of title 38, United States Code. 

Æ 


ssavage on LAPJG3WLY3PROD with BILLS
I 

118TH CONGRESS 

2D SESSION H. R. 7695 

To prohibit deployment of Federal air marshals to the southern and northern 

borders of the United States, and for other purposes. 

IN THE HOUSE OF REPRESENTATIVES 

MARCH 15, 2024 

Mrs. HINSON (for herself and Mr. PFLUGER) introduced the following bill; 

which was referred to the Committee on Homeland Security 

A BILL 

To prohibit deployment of Federal air marshals to the southern and northern borders of the United States, and 

for other purposes. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘No FAMS at the Bor5 der Act of 2024’’. 

6 SEC. 2. PROHIBITION ON DEPLOYMENT. 

7 (a) IN GENERAL.—Section 44917 of title 49, United 

8 States Code, is amended by adding at the end the fol9 lowing: 

10 ‘‘(d) PROHIBITION ON DEPLOYMENT.— 


ssavage on LAPJG3WLY3PROD with BILLS
2 

•HR 7695 IH

1 ‘‘(1) DEFINITIONS.—In this subsection: 

2 ‘‘(A) ALIEN.—The term ‘alien’ has the 

3 meaning given that term in section 101 of the 

4 Immigration and Nationality Act (8 U.S.C. 

5 1101). 

6 ‘‘(B) APPROPRIATE CONGRESSIONAL COM7 MITTEES.—The term ‘appropriate congressional 

8 committees’ means— 

9 ‘‘(i) the Committee on Commerce, 

10 Science, and Transportation of the Senate; 

11 and 

12 ‘‘(ii) the Committee on Homeland Se13 curity of the House of Representatives. 

14 ‘‘(C) ILLEGAL ALIEN.—The term ‘illegal 

15 alien’ means an alien who has not been admit16 ted (as that term is defined in section 101 of 

17 the Immigration and Nationality Act (8 U.S.C. 

18 1101)). 

19 ‘‘(D) IMMIGRANT.—The term ‘immigrant’ 

20 has the meaning given that term in section 101 

21 of the Immigration and Nationality Act (8 

22 U.S.C. 1101). 

23 ‘‘(2) IN GENERAL.—Except as provided in para24 graph (3) and notwithstanding any other provision 

25 of law, including section 103 of the Immigration and 


ssavage on LAPJG3WLY3PROD with BILLS
3 

•HR 7695 IH

1 Nationality Act (8 U.S.C. 1103), Federal air mar2 shals may not be deployed to the southern or north3 ern border of the United States for border security 

4 or immigration purposes, including to aid the De5 partment of Homeland Security or any other Fed6 eral agency with the processing of illegal aliens, or 

7 any other immigrants. 

8 ‘‘(3) EXCEPTIONS.— 

9 ‘‘(A) EXCEPTION IN CASE OF BORDER CRI10 SIS.—Paragraph (2) shall not apply if the Sec11 retary of Homeland Security— 

12 ‘‘(i) determines that a border crisis 

13 exists; and 

14 ‘‘(ii) certifies to the appropriate con15 gressional committees in writing that a 

16 border crisis exists. 

17 ‘‘(B) NONDELEGATION.—The Secretary 

18 may not delegate the authority to make a deter19 mination or certification described in subpara20 graph (A).’’. 

21 (b) TECHNICAL AMENDMENT.—Section 44917(b) of 

22 title 49, United States Code, is amended by striking 

23 ‘‘Under Secretary’’ each place it appears and inserting 

24 ‘‘Administrator’’. 

Æ 


ssavage on LAPJG3WLY3PROD with BILLS
§ 74.1255 D&C Orange No. 5. ( a ) *Identity.* ( 1 ) the color additive D&C Orange No. 5 is a mixture consisting principally the sodium salt of 4′,5′-dibromofluorescein (CAS Reg. No. 596-03-2) and 2′,4′,5′-tribromofluorescein (CAS Reg. No. 25709-83-5) and 2′,4′,5′,7′-tetrabromofluorescein (CAS Reg. No. 15086-94-9). D&C Orange No. 5 is manufactured by brominating fluorescein with elemental bromine. The fluorescein is manufactured by the acid condensation of resorcinol and phthalic acid or its anhydride. The fluorescein is isolated and partially purified prior to bromination.
( 2 ) Color additive mixtures for drug use made with D&C Orange No. 5 may contain only those diluents that are suitable and that are listed in part 73 of this chapter for use in color additive mixtures for coloring drugs.
( b ) *Specifications.* D&C Orange No. 5 shall conform to the following specifications and shall be free from impurities other than those named to the extent that such impurities may be avoided by good manufacturing practice. 4′,5′-dibromofluorescein, not less than 50 percent and not more than 65 percent. 2′,4′,5′-tribromofluorescein, not less than 30 percent and not more than 40 percent. 2′,4′,5′,7′-tetrabromofluorescein, not more than 10 percent. Sum of 2′,4′-dibromofluorescein and 2′,5′-dibromofluorescein, not more than 2 percent. 4′-Bromofluorescein, not more than 2 percent. Fluorescein, not more than 1 percent. Phthalic acid, not more than 1 percent. 2-(3,5-Dibromo-2,4-dihydroxybenzoyl) benzoic acid, not more than 0.5 percent. Brominated resorcinol, not more than 0.4 percent. Sum of volatile matter (at 135 °C) and halides and sulfates (calculated as sodium salts), not more than 10 percent. Insoluble matter (alkaline solution), not more than 0.3 percent. Lead (as Pb), not more than 20 parts per million. Arsenic (as As), not more than 3 parts per million. Mercury (as Hg), not more than 1 part per million. Total color, not less than 90 percent.
( c ) *Uses and restrictions.* D&C Orange No. 5 may be safely used for coloring mouthwashes and dentifrices that are ingested drugs in amounts consistent with current good manufacturing practice. D&C Orange No. 5 may be safely used in externally applied drugs in amounts not exceeding 5 milligrams per daily dose of the drug.
( d ) *Labeling.* The label of the color additive and any mixtures prepared therefrom intended solely or in part for coloring purposes shall conform to the requirements of § 70.25 of this chapter.
( e ) *Certification.* All batches of D&C Orange No. 5 shall be certified in accordance with regulations in part 80 of this chapter.
[47 FR 44635, Nov. 2, 1982, as amended at 49 FR 13342, Apr. 4, 1984]